U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28O5
Molecular Weight 360.444
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PREDNISOLONE

SMILES

[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H28O5
Molecular Weight 360.444
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Primary
Prednisolone

Approved Use

Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Launch Date

-4.6120321E11
Palliative
Sixtysix-20

Approved Use

Antiinflammatory agent
Primary
OMNIPRED

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

1.11023997E11
Primary
OMNIPRED

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

1.11023997E11
Primary
OMNIPRED

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

1.10937604E11
Primary
OMNIPRED

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

1.10937604E11
Primary
OMNIPRED

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

1.10937604E11
Curative
Prednisolut

Approved Use

Prednisolut is indicated in shock and emergency medicine: Shock due to a severe allergic reaction (anaphylactic shock), after previous treatment with epinephrine, progressive forms of allergic reactions in insect bites and snake bites
Primary
Prednisolut

Approved Use

Brain swelling (brain edema), triggered by brain tumor, neurosurgery, brain abscess, bacterial meningitis (meningitis).
Primary
Prednisolut

Approved Use

Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Primary
Prednisolut

Approved Use

Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Primary
Prednisolut

Approved Use

Prednisolut is indicated for treatment of severe / life-threatening situations in the following rheumatic diseases: rheumatoid arthritis and still syndrome, felty syndrome, polymyalgia rheumatica, systemic juvenile idiopathic arthritis (eg breast disease, seropositive polyarthritis), collagenoses, vasculitides, rheumatic fever.
PubMed

PubMed

TitleDatePubMed
[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate].
1987 Feb
Comparison of suppressive potency between prednisolone and prednisolone sodium succinate against mitogen-induced blastogenesis of human peripheral blood mononuclear cells in-vitro.
2001 May
Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia.
2008 Apr
Patents

Sample Use Guides

Two drops topically in the eye(s) four times daily.
Route of Administration: Other
In Vitro Use Guide
Human polymorphonuclear leukocytes (PMNLs) were incubated for 60 min with 20 microM or 100 microM prednisolone, and stimulated thereafter for 1 min with 10 nM leukotriene B4 (LTB4), 10 nM leukotriene C4 (LTC4), 10 nM leukotriene D4 (LTD4) or 10 microM histamine. PMNLs spontaneously released thromboxane B2 (TXB2) during 60 min incubation, and the rate of formation was significantly reduced in the presence of 20 microM or 100 microM prednisolone. LTB4, LTC4, LTD4, and histamine stimulated the rate of TXB2 production during 1 min incubation to 93-, 49-, 60-, and 55-fold, respectively.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:45:59 UTC 2023
Edited
by admin
on Wed Jul 05 22:45:59 UTC 2023
Record UNII
9PHQ9Y1OLM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PREDNISOLONE
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Common Name English
METI-DERM
Brand Name English
NSC-9120
Code English
METHYLPREDNISOLONE IMPURITY K [EP IMPURITY]
Common Name English
NSC-9900
Code English
11.BETA.,17,21-TRIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE.
Common Name English
11β,17,21-Trihydroxypregna-1,4-diene-3,20-dione
Systematic Name English
PREDNISOLONE (EMA EPAR: VETERINARY)
Common Name English
PREDNISOLONE [MART.]
Common Name English
PREDNISOLONE COMPONENT OF CHLOROPTIC-P S.O.P.
Common Name English
(+)-PREDNISOLONE
Common Name English
PREDNISOLONE [ORANGE BOOK]
Common Name English
PREDNISONE IMPURITY B [EP]
Common Name English
PREDNISOLONE ANHYDROUS
Common Name English
DELTAHYDROCORTISONE
Common Name English
APREDNISLON
Common Name English
PREDNISOLONE [EP]
Common Name English
PREDNICARBATE IMPURITY A [EP IMPURITY]
Common Name English
Prednisolone [WHO-DD]
Common Name English
DELTA-CORTEF
Brand Name English
PREDNISOLONE [JAN]
Common Name English
EQUISOLON
Brand Name English
PREDNISOLONE [HSDB]
Common Name English
PREDNISOLONE ACETATE IMPURITY B [EP IMPURITY]
Common Name English
PANAFCORTELONE
Common Name English
HYDRORETROCORTINE
Common Name English
PREDNISOLONUM [WHO-IP LATIN]
Common Name English
prednisolone [INN]
Common Name English
CODELCORTONE
Common Name English
FERNISOLONE-P
Brand Name English
PREDNISOLONE [MI]
Common Name English
PREDNISOLONE [EP MONOGRAPH]
Common Name English
PREDNISOLONE [VANDF]
Common Name English
PREDNISOLONE [USP-RS]
Common Name English
PREDNISOLONE [GREEN BOOK]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA)-
Common Name English
SUPERCORTISOL
Common Name English
DELTACORTRIL
Brand Name English
PREDNISOLONE [WHO-IP]
Common Name English
PREDNISOLONE [USP MONOGRAPH]
Common Name English
METACORTANDRALONE
Common Name English
STERANE
Brand Name English
VETSOLONE
Common Name English
CORTALONE
Brand Name English
HYDROCORTISONE IMPURITY A [EP IMPURITY]
Common Name English
Classification Tree Code System Code
WHO-VATC QS03CA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QS01CB02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QA01AC54
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
NDF-RT N0000175576
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S01CA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC D07CA03
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC C05AA04
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S01CB02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC A01AC54
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S02CA01
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QC05AA04
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 520.1880
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
NDF-RT N0000175450
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 520.2604
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QD07XA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QH02AB56
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QS02BA03
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 524.1484K
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S01BB02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 520.2345H
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 524.1484F
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
NCI_THESAURUS C521
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC A07EA01
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QD07CA03
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
EMA VETERINARY ASSESSMENT REPORTS EQUISOLON (AUTHORISED)
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC V03AB05
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QS01CA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S03BA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S01BA04
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QD07BA01
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 524.1445
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC R01AD52
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC H02AB06
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QS03BA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QS01BA04
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S02BA03
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC R01AD02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC D07AA03
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC D07BA01
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QR01AD52
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 21.2
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QS02CA01
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QR01AD02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QD07AA03
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC S03CA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QV03AB05
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QH02AB06
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 520.2605
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-ATC D07XA02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QA07EA01
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
LIVERTOX 794
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 522.1885
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
CFR 21 CFR 524.1484J
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
WHO-VATC QS01BB02
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
Code System Code Type Description
NSC
9900
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
DRUG CENTRAL
2245
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
MERCK INDEX
M9111
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
PREDNISOLONE
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
PUBCHEM
5755
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
EVMPD
SUB10018MIG
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PREDNISOLONE
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility. Soluble in 1300 parts of water and in 30 parts of dehydrated ethanol R; soluble in methanol R and dioxan R. Category: Adrenocortical steroid. Storage: Prednisolone should be kept in a tightly closed container, protected from light. Additional information: Prednisolone is hygroscopic; it has a melting temperature of about 230?C with decomposition. Definition: Prednisolone contains not less than 97.0% and not more than 102.0% of C21H28O5, calculated with reference to thedried substance.
RXCUI
8638
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY RxNorm
FDA UNII
9PHQ9Y1OLM
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
NCI_THESAURUS
C769
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
RS_ITEM_NUM
1555005
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
EPA CompTox
DTXSID9021184
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
DAILYMED
9PHQ9Y1OLM
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
HSDB
3385
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
DRUG BANK
DB00860
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
INN
535
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
SMS_ID
100000091520
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
ChEMBL
CHEMBL131
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
CAS
50-24-8
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
IUPHAR
2866
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
MESH
D011239
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
CAS
8056-11-9
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
SUPERSEDED
ECHA (EC/EINECS)
200-021-7
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
NSC
9120
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
LACTMED
Prednisolone
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
CHEBI
8378
Created by admin on Wed Jul 05 22:46:00 UTC 2023 , Edited by admin on Wed Jul 05 22:46:00 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
BINDER->LIGAND
BINDING LARGELY TO ALBUMIN; DOSAGE SHOULD BE REDUCED IN HYPOALBUMINANEMIA
BINDING
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC